Granados-González Viviana, Piedrahita Leidy Diana, Martínez Marlen, Genin Christian, Riffard Serge, Urcuqui-Inchima Silvio
Groupe Immunité des Muqueuses et Agents Pathogènes, University of Saint Etienne, Saint Etienne, Francia.
Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1.
The development of a preventive vaccine against human immunodeficiency virus type-1 (HIV-1) provides hope for control of the pandemic over the coming years. Nevertheless, it is clear that one of the greatest difficulties in achieving this vaccine is the high mutation rate of the virus, which enables it to evade the host's immune response. The production of neutralizing antibodies (NAb) against the HIV-1 envelope proteins is believed to play an important role in controlling the infection and in providing effective protection following vaccination. Several studies have shown that the V1/V2 domain of the HIV-1 gp120 envelope protein is involved in viral tropism during infection, in masking conserved neutralizing epitopes, in the conformational changes occurring after coreceptor binding, and in NAb induction. Nonetheless, this domain has been poorly investigated. However, because the V1/V2 domain is highly glycosylated, numerous studies have determined the influence of carbohydrates on NAb production. The present review focuses on the importance of NAb directed against epitopes of the variable regions, mainly V1/V2, their importance in protecting against HIV-1 infection, and the role these regions play in evading the immune response. Lastly, we will discuss the importance of NAb in the search for an effective vaccine against HIV-1.
开发针对1型人类免疫缺陷病毒(HIV-1)的预防性疫苗为未来几年控制这一全球性流行病带来了希望。然而,很明显,实现这种疫苗面临的最大困难之一是该病毒的高突变率,这使其能够逃避宿主的免疫反应。产生针对HIV-1包膜蛋白的中和抗体(NAb)被认为在控制感染以及接种疫苗后提供有效保护方面发挥着重要作用。多项研究表明,HIV-1 gp120包膜蛋白的V1/V2结构域在感染期间参与病毒嗜性、掩盖保守的中和表位、共受体结合后发生的构象变化以及NAb诱导。尽管如此,该结构域的研究较少。然而,由于V1/V2结构域高度糖基化,众多研究已经确定了碳水化合物对NAb产生的影响。本综述重点关注针对可变区(主要是V1/V2)表位的NAb的重要性、它们在预防HIV-1感染中的重要性以及这些区域在逃避免疫反应中所起的作用。最后,我们将讨论NAb在寻找针对HIV-1的有效疫苗中的重要性。